Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares

Key Points

• Insider transaction: VP Daniel Lippis sold 619 Edwards Lifesciences shares for approximately $54,169 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 1.52% to 40,034 shares.
• Strong financial performance: Edwards reported quarterly EPS of $0.78 versus the $0.74 consensus estimate, while revenue increased 13.6% year over year to $1.74 billion. Management maintained 2026 EPS guidance of $2.95–$3.05.
• Positive outlook: Expanded Medicare coverage for certain asymptomatic aortic stenosis patients could boost demand for the company’s TAVR procedures. Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $100.27 versus the recent $84.54 share price.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 619 shares of the firm's stock in a transaction on Friday, September 11th. The stock was sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the transaction, the vice president owned 40,034 shares of the company's stock, valued at $3,503,375.34. This trade represents a 1.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $2.23 during trading hours on Friday, hitting $84.54. 3,795,187 shares of the stock traded hands, compared to its average volume of 2,600,847. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm's 50 day moving average price is $89.16 and its 200-day moving average price is $85.79. The stock has a market capitalization of $48.68 billion, a price-to-earnings ratio of 48.59, a P/E/G ratio of 2.28 and a beta of 0.85. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. During the same period last year, the business posted $0.67 earnings per share. The company's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth $266,000. NewEdge Advisors LLC grew its holdings in Edwards Lifesciences by 8.1% during the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock worth $2,787,000 after acquiring an additional 2,665 shares in the last quarter. Sei Investments Co. increased its holdings in Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock valued at $32,285,000 after buying an additional 58,988 shares during the last quarter. Squarepoint Ops LLC lifted its stake in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock worth $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock worth $21,028,000 after buying an additional 1,065 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EW. TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Piper Sandler reaffirmed an "overweight" rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Evercore reiterated an "outperform" rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $100.27.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

About Edwards Lifesciences

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.